Distribuzione geografica
Continente #
NA - Nord America 2249
EU - Europa 519
AS - Asia 250
SA - Sud America 19
AF - Africa 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 3050
Nazione #
US - Stati Uniti d'America 2230
IT - Italia 181
SE - Svezia 145
IN - India 132
CN - Cina 109
FI - Finlandia 54
UA - Ucraina 51
IE - Irlanda 25
DE - Germania 24
CA - Canada 19
AR - Argentina 16
BE - Belgio 11
TG - Togo 11
NL - Olanda 8
RO - Romania 8
TR - Turchia 8
GB - Regno Unito 7
CL - Cile 3
FR - Francia 2
BG - Bulgaria 1
DK - Danimarca 1
EU - Europa 1
IR - Iran 1
RU - Federazione Russa 1
ZA - Sudafrica 1
Totale 3050
Città #
Fairfield 384
Chandler 214
Woodbridge 181
Ann Arbor 142
Ashburn 142
Houston 133
Seattle 131
Cambridge 112
Wilmington 110
Beijing 85
Princeton 79
Rome 76
Plano 58
Fremont 49
Dearborn 40
Boston 38
Lawrence 38
San Diego 32
Millbury 26
Dublin 25
San Paolo di Civitate 24
Des Moines 22
Jacksonville 20
Federal 16
Andover 15
Lomé 11
Ottawa 11
Norwalk 9
Brussels 8
Istanbul 8
Toronto 8
Falls Church 6
Milan 5
Redmond 5
Boardman 4
Bremen 4
Kunming 4
Nanjing 4
San Mateo 4
Frankfurt am Main 3
Fuzhou 3
Phoenix 3
Amsterdam 2
Casarile 2
Florence 2
Foggia 2
Guangdong 2
Hefei 2
Indiana 2
Leawood 2
London 2
Redwood City 2
Sacramento 2
San Francisco 2
Shanghai 2
Waanrode 2
Yellow Springs 2
Aiello Del Sabato 1
Arnsberg 1
Bagnacavallo 1
Bari 1
Buffalo 1
Chengdu 1
Chongqing 1
Copenhagen 1
Den Haag 1
Duncan 1
Grottaferrata 1
Guangzhou 1
Hebei 1
Helsinki 1
Latina 1
Laurel 1
Miami 1
Naples 1
Napoli 1
Nurallào 1
Pescara 1
Rho 1
Saint Louis 1
San Benedetto Ullano 1
Santiago 1
Silverton 1
Sofia 1
Southend 1
Westminster 1
Wuhan 1
Totale 2352
Nome #
Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism 134
Spectrum of mutations and long-term clinical outcomes in genetic chylomicronemia syndromes 91
Evaluation of polygenic determinants of non-alcoholic fatty liver disease (NAFLD) by a candidate genes resequencing strategy 87
Association of RXR-Gamma Gene Variants with Familial Combined Hyperlipidemia: Genotype and Haplotype Analysis 82
Atherogenic dyslipidemia in children: evaluation of clinical, biochemical and genetic aspects. 82
Genetic variants in adipose triglyceride lipase influence lipid levels in familial combined hyperlipidemia 81
Non-alcoholic fatty liver disease and subclinical atherosclerosis: a comparison of metabolically- versus genetically-driven excess fat hepatic storage 80
C242T polymorphism of NADPH oxidase p22phox and recurrence of cardiovascular events in coronary artery disease 78
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke 76
Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach 75
PON1 L55M polymorphism is not a predictor of coronary atherosclerosis either alone or in combination with Q192R polymorphism in an Italian population 74
Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment 74
5-lipoxygenase variant genotype as an inherited risk factor for myocardial infarction modifiable by n-3 fatty acid supplementation 72
Angptl3 deficiency is associated with increased insulin sensitivity, lipoprotein lipase activity, and decreased serum free fatty acids 72
Analysis of Children and Adolescents with Familial Hypercholesterolemia 70
Functional and morphological vascular changes in subjects with familial combined hypolipidemia: An exploratory analysis 67
Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia 66
Clinical and biochemical characterisation of patients with autosomal recessive hypercholesterolemia (ARH) 66
Angiotensin-converting enzyme gene polymorphism is not associated with coronary atherosclerosis and myocardial infarction in a sample of Italian patients 65
A novel splicing mutation in the ABCA1 gene, causing Tangier disease and familial HDL deficiency in a large family 64
Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN) 61
Functional rs20417 SNP (-765G > C) of Cyclooxygenase-2 Gene Does Not Predict the Risk of Recurrence of Ischemic Events in Coronary Patients: Results of a 7-Year Prospective Study 60
Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study 60
Continuous case finding of familial hypercholesterolemia (FH): screening of a cohort of italian children with hypercholesterolemia. 57
Detection of familial hypercholesterolemia in a cohort of children with hypercholesterolemia: Results of a family and DNA-based screening 57
Evolving trend in the management of heterozygous familial hypercholesterolemia in Italy: a retrospective, single center, observational study 57
The gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in italian patients 57
Plasma cholesterol response to a change in dietary fat intake: A collaborative twin study 56
Genetic determinants of dyslipidemia associated with the insulin resistance syndrome (IRS) 51
Lack of association between arterial blood pressure and erythrocyte fatty acid composition in an Italian population sample 49
Circulating miR-33a and miR-33b increase in familial hypercholesterolemia in paediatric age 46
Plasma non-cholesterol sterols: a useful diagnostic tool in pediatric hypercholesterolemia. 46
null 45
Insulin receptor substrate-1 gene variant in extracoronary atherosclerosis: Evidence for an association with increased risk of ischemic stroke 44
Interleukin-1 gene cluster polymorphisms and risk of coronary artery disease 41
An improved gas liquid chromatographic method for the determination of fecal neutral sterols 40
Lack of association of the common TaqIB polymorphism in the cholesterol ester transfer protein gene with angiographically assessed coronary atherosclerosis. 40
null 39
Erythrocyte fatty acid composition and gallstone disease: results of an epidemiological survey 39
Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: implications for clinical diagnosis 39
Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: Focus on β2GPI-Specific T cell response 37
Uric acid levels in metabolic syndrome, type 2 diabetes and familial combined hyperlipidemia: a comparison 37
Comparison of subjective and objective methods of estimating lipid intake 36
The molecular basis of Lecithin Choleesterol Acyltransferase Deficiency Sindrome. A comprehensive study of molecular and biochemical findings in 13 italian families 35
The metabolic basis of a new form of recessive hypercholesterolemia: the "FH-like" hypercholesterolemia 35
Phenotype expression in Italian families with Familial Combined Hypercholesterolemia (FCHL): The Familial Combined Hypercholesterolemia Genetic Study 33
Mutations in the ANGPTL3 gene and familial combined hypolipidemia: A clinical and biochemical characterization 33
A common mutation in the insulin receptor substrate-1 gene is a genetic marker for the insulin resistance syndrome in patients with coronary artery disease 32
Analisi mutazionale dei geni ApoA1 e LPL nella dislipidemia aterogena in età pediatrica 32
Genome wide search for linkage mapping of susceptibility genes for familial combined hyperlipidemia (FCHL) 31
Frequency of carriers of autosomal recessive hypercholesterolemia (ARH) in the Sardinian population: Preliminary results 27
Il ruolo dei fattori genetici nella suscettibilità individuale all'aterosclerosi coronarica 26
The common variants in the lipoprotein lipase (LPL) gene, but not those in the insulin receptor substrate-1 (IRS-1), the beta 3 adrenergic receptor (beta3AR) and the intestinal fatty acids binding protein-2 (FABP-2) genes influence the lipid phenotypic expression in familial combined hyperlipidemia 26
Does intervention on glycemic control influence HDL cholesterol levels in type 2 diabetes? A pilot study 25
Efficacy and safety of atorvasatin vs.fenofibrate in familial combined hyperlipidemia (FCHL). A randomized, pilot, comparative study 23
null 23
Prevalenza della colelitiasi: osservazioni preliminari su un campione di popolazione lavorativa femminile. 22
Atherogeniic dyslipidemia in metabolic syndrome, type 2 diabetes and familial combined hyperlipemia: lipid and lipoproteins profiling 20
The common polymorphisms in the lipoprotein lipase (LPL) gene in Italy: prevalence in the general population and effects on plasma lipids. 20
Sovrappeso corporeo e pressione arteriosa in un campione di bambini in età scolare 19
Metodica gascromatografica per il dosaggio degli sterolo neutri fecali 19
The cholesterol ester transfer protein (CETP) TaqIB variant, HDL cholesterol levels, cardiovascular risk and the efficacy of pravastatin treatment – an individual patient meta-analisis of 13,677 subjects 18
Short-term treatment with a lipid-lowering agent: diethylamino-ethyldextran (Dexide) 15
Clinical implications of monogenic versus polygenic hypercholesterolemia: Long-term response to treatment, coronary atherosclerosis burden, and cardiovascular events 8
Autophagy in development and regeneration: role in tissue remodelling and cell survival 7
Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events. 1
Totale 3201
Categoria #
all - tutte 5491
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 5491

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019354 901212 1610 40 35913099
2019/2020791 10223824 71102 12876 871124216
2020/2021381 3424926 961 1037 4296294
2021/2022743 1436221 8824 1661 6161182123
2022/2023693 1421304575 7481 1940 675150
Totale 3201